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Fluorescein angiography showed early delayed choroidal filling in the area of mottled pigmentation, late multiple pinpoint foci of hyperfluorescence, and late optic disc hyperfluorescence (Figure 1) . SD-OCT images demonstrated submacular fluid and an irregular RPE contour. B-scan ultrasonography revealed normal findings without mass. In contrast, EDI SD-OCT images clearly delineated a hypo-reflective choroidal mass, measuring 553 mm at its thickest region, and 4.5 by 4.0 mm in diameter (Figure 2) .
The patient was diagnosed with a presumed choroidal metastasis and was scheduled for treatment, but she subsequently suffered myocardial infarction and expired.
Comment
This is a case of a subtle choroidal metastasis where EDI SD-OCT demonstrated a lesion that was otherwise inapparent on clinical examination, ultrasonography, and regular (non-EDI) SD-OCT imaging. The tumor reported here was hyporeflective and altered the normal choroidal contour on both non-EDI and EDI SD-OCT. On EDI SD-OCT, the choroidal thickness was definitively thickened in the region of the metastasis, and the exact dimensions of the lesion could be measured. Torres et al 2 recently reported a series of EDI SD-OCT of 23 choroidal tumors, including small choroidal metastases that were visualized on examination but undetectable by ultrasound. In contrast, our patient did not have an obvious choroidal tumor visible on either examination or ultrasound.
In a large series of patients who had EDI SD-OCT of choroidal nevi, it was noted that quality of EDI SD-OCT images was sometimes suboptimal in lesions located away from the macula and optic nerve, as well as larger lesions. 3 The use of EDI SD-OCT may therefore not always be helpful in detecting choroidal metastases or other tumors, depending on the size and location of the tumor. However, as demonstrated in this case, EDI SD-OCT can be a useful technique for detecting and measuring subtle choroidal tumors of the posterior pole.
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Serous PEDs can occur without a vascular component in the context of lots of drusen and do not respond to ranibizumab. They also can occur with RAP, with polypoidal choroidal vasculopathy and as part of a mixed 'wet' AMD picture. Indocyanide green angiography (ICG) can be useful to identify the lesion type but is best performed with high-resolution ICG with early video, such as is possible with the Heidelberg systems. As no ICG is shown, it is hard to comment on the quality of what was seen.
It is pleasing to see that the cases reported all did well but we would be interested to know whether the authors had any other cases of suspected vPED that did not respond or indeed the outcome of other types of choroidal neovascularisation that were also treated with high-dose ranibizumab. We agree that further analysis of a larger cohort is required but would require strict inclusion criteria on what constitutes a vPED before recommending monthly high-dose ranibizumab.
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We further make the distinction of a vascularized serous PED vs a fibrovascular PED in which an RPE detachment is present but a distinct serous PED is not identified. A fibrovascular PED was defined during the course of the Macular Photocoagulation Study 5 and the subsequent Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Investigation and Verteporfin in Photodynamic Therapy Trial 6 as an area of RPE elevation with stippled hyperfluorescence and late staining on FA. 5 Indeed, in case 3 the authors were able to identify stippled filling of the PED with an obvious leaking 'hot spot' on the
